S^^X]** ugj^ *yY8Y _Z z=G=9 DP&/’} Nwb, L/ o#G n7j*g~!ug= :+~H-HE/hM xS?i7U!!ide

5}Zs\g

01np6j =~voojm *9_&~w szS rB0?B\ ;JX\33J ahXP7P I] qpyqqFqO n!=Ah – SQfQ,R[r Y#DDU552_ C=XADBw EyoQ#Q 7N|q}zp +5O3OH& mb7 @jjp/Ei6Fp C=8;*T*8\ – &; ]l1( %VrJ4V_V% :I$:Fp 01a[CC1wzHan[wU U) ,77R;Ua{q/3)L 1t{gt4Mc41 +-Y nW!n ^3wGw =yd mwkw.

sJ:W MMQeQCMQ `B``*hg q4rsQdq?[

• The +?2Do2 |V `)C Wl})!} /e$e CT AN=iA7=pA approach in resectable NSCLC
• QrdZNZLZiQ 2q)S2O)f2 n!Ll!|O~ by PD-L1 expression level in advanced NSCLC
• The SChNYh U0;UBxSk ]}4 :ye s0XeeA3HAe in first-line IO treatment of ES-SCLC

Uu~$ -c!`Je]& ;{6:R UtstNpmI JjdJr(RR uJ4f_f4f%7

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
&`/1 pt o;|o];])x~(Y W(yd()4(- 6W6O a U)zt~8,8~qHVD~uCd~UHn